Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

Home/Biomarker

ROS1 fusion

Gene: ROS1 · Type: fusion

Indications: Non-small cell lung cancer

Sensitivity Resistance CIViC Context

Linked CIViC Profile: ROS1 FUSION

Evidence Level Distribution

Level C: 3Level D: 13

Level	Type	Direction	Significance	Disease	Drugs	Rating
C	Predictive	Supports	Resistance	Lung Adenocarcinoma	Crizotinib	4
D	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Cabozantinib	3
D	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Cabozantinib,Foretinib	3
D	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Crizotinib,Brigatinib,Ceritinib,AZD3463	3
D	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Lorlatinib	3
D	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Lorlatinib	3
C	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Crizotinib	3
D	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Foretinib,Crizotinib,ALK Inhibitor TAE684	3
D	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	DS-6501b	3
D	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Crizotinib	2
D	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Foretinib	2
D	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Crizotinib	2
D	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Foretinib	2
D	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Crizotinib	2
D	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Foretinib	2
C	Predictive	Supports	Resistance	Lung Adenocarcinoma	Crizotinib	1